Genetic variations in AURORA cell cycle kinases are associated with glioblastoma multiforme.
Adolescent
Adult
Aged
Aged, 80 and over
Aurora Kinase A
/ genetics
Aurora Kinase B
/ genetics
Aurora Kinase C
/ genetics
Biomarkers, Tumor
/ genetics
Case-Control Studies
Cell Cycle Proteins
/ genetics
Female
Follow-Up Studies
Genotype
Glioblastoma
/ genetics
Humans
M Phase Cell Cycle Checkpoints
Male
Middle Aged
Polymorphism, Single Nucleotide
Prognosis
Protein Serine-Threonine Kinases
/ genetics
Proto-Oncogene Proteins
/ genetics
Young Adult
Polo-Like Kinase 1
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 08 2021
31 08 2021
Historique:
received:
17
06
2021
accepted:
18
08
2021
entrez:
1
9
2021
pubmed:
2
9
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is the most frequent type of primary astrocytomas. We examined the association between single nucleotide polymorphisms (SNPs) in Aurora kinase A (AURKA), Aurora kinase B (AURKB), Aurora kinase C (AURKC) and Polo-like kinase 1 (PLK1) mitotic checkpoint genes and GBM risk by qPCR genotyping. In silico analysis was performed to evaluate effects of polymorphic biological sequences on protein binding motifs. Chi-square and Fisher statistics revealed a significant difference in genotypes frequencies between GBM patients and controls for AURKB rs2289590 variant (p = 0.038). Association with decreased GBM risk was demonstrated for AURKB rs2289590 AC genotype (OR = 0.54; 95% CI = 0.33-0.88; p = 0.015). Furthermore, AURKC rs11084490 CG genotype was associated with lower GBM risk (OR = 0.57; 95% CI = 0.34-0.95; p = 0.031). Bioinformatic analysis of rs2289590 polymorphic region identified additional binding site for the Yin-Yang 1 (YY1) transcription factor in the presence of C allele. Our results indicated that rs2289590 in AURKB and rs11084490 in AURKC were associated with a reduced GBM risk. The present study was performed on a less numerous but ethnically homogeneous population. Hence, future investigations in larger and multiethnic groups are needed to strengthen these results.
Identifiants
pubmed: 34465813
doi: 10.1038/s41598-021-96935-y
pii: 10.1038/s41598-021-96935-y
pmc: PMC8408269
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell Cycle Proteins
0
Proto-Oncogene Proteins
0
AURKA protein, human
EC 2.7.11.1
AURKB protein, human
EC 2.7.11.1
AURKC protein, human
EC 2.7.11.1
Aurora Kinase A
EC 2.7.11.1
Aurora Kinase B
EC 2.7.11.1
Aurora Kinase C
EC 2.7.11.1
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
17444Subventions
Organisme : EPA
ID : EP-C-15-010
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Mol Biol Cell. 2009 Nov;20(22):4766-76
pubmed: 19793915
Indian J Clin Biochem. 2015 Apr;30(2):134-9
pubmed: 25883419
Int J Med Sci. 2014 Aug 22;11(11):1147-53
pubmed: 25170298
Nat Rev Drug Discov. 2010 Aug;9(8):643-60
pubmed: 20671765
Cell. 1995 Apr 7;81(1):95-105
pubmed: 7720077
Int J Clin Exp Med. 2015 Sep 15;8(9):16724-8
pubmed: 26629211
Breast Cancer Res Treat. 2007 Dec;106(2):205-13
pubmed: 17268814
Nat Rev Mol Cell Biol. 2018 Mar;19(3):158-174
pubmed: 29165424
Int J Cancer. 2006 Jul 15;119(2):275-82
pubmed: 16477625
Mol Cancer. 2015 May 20;14:106
pubmed: 25987188
Curr Biol. 2015 Jan 19;25(2):131-140
pubmed: 25532896
Nat Rev Cancer. 2010 Dec;10(12):825-41
pubmed: 21102634
Clin Cancer Res. 2008 Mar 15;14(6):1639-48
pubmed: 18347165
PLoS One. 2011;6(10):e26512
pubmed: 22046298
Br J Radiol. 2012 Sep;85(1017):e729-33
pubmed: 22215883
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W74-8
pubmed: 21576231
Cell Cycle. 2011 Jul 15;10(14):2255-62
pubmed: 21654194
J Cell Biol. 2006 Jun 19;173(6):833-7
pubmed: 16769825
Mol Hum Reprod. 2015 Aug;21(8):633-44
pubmed: 25995441
Nucleic Acids Res. 2003 Jul 1;31(13):3651-3
pubmed: 12824386
Cell Motil Cytoskeleton. 2004 Dec;59(4):249-63
pubmed: 15499654
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7507-12
pubmed: 19372376
Bioinformatics. 2002 Feb;18(2):333-4
pubmed: 11847087
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W600-5
pubmed: 19417063
Asian Pac J Cancer Prev. ;18(1):3-9
pubmed: 28239999
PLoS One. 2012;7(10):e46784
pubmed: 23082130
Nucleic Acids Res. 2020 Jan 8;48(D1):D682-D688
pubmed: 31691826
J Pathol. 2011 Oct;225(2):243-54
pubmed: 21710690
Histol Histopathol. 2007 Feb;22(2):191-7
pubmed: 17149692
Nat Rev Gastroenterol Hepatol. 2014 Nov;11(11):664-74
pubmed: 25134511
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Cold Spring Harb Protoc. 2009 Oct;2009(10):pdb.ip71
pubmed: 20147036
Nucleic Acids Res. 2017 Jan 4;45(D1):D139-D144
pubmed: 27899579
Oncotarget. 2017 Apr 4;8(14):23937-23954
pubmed: 28147341
Ann Transl Med. 2015 Jan;3(1):7
pubmed: 25705639
Mol Cell Biol. 2015 Oct;35(20):3566-78
pubmed: 26240282
Mol Cancer. 2014 Apr 26;13:87
pubmed: 24767679
Protein Sci. 2018 Jan;27(1):316-330
pubmed: 29067736
Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):84-90
pubmed: 16002116
J Clin Med Res. 2015 Oct;7(10):742-51
pubmed: 26345296
Oncogene. 2006 Feb 23;25(8):1125-42
pubmed: 16314846